ClinicalTrials.gg
CompletedNCT00866944MT201-204Updated Nov 11, 2011

Study of Adecatumumab Relative to FOLFOX After R0 Resection of Colorectal Liver Metastases

A Phase 2 interventional study of Adecatumumab and Adecatumumab and FOLFOX in Liver Metastases and Colorectal Cancer, sponsored by Amgen Research (Munich) GmbH. Completed at 16 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-11-11.

Sponsored by Amgen Research (Munich) GmbH (part of Amgen) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
35
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 37 studies testing Folfox protocol in Colorectal Neoplasms — 14 open to participants now, 17 under way, 3 of them phase 3. Folfox protocol · Colorectal Neoplasms.

Enrollment
28th of 37
35 · median 102
Started
2009
with 4 others
Phase 2
19 of 37
8 open now
Registered
10th of 37
by date
Lead sponsor
1 of 37
Amgen Research (Munich) GmbH

Among the 37 studies testing Folfox protocol in Colorectal Neoplasms, this one is the 28th largest by enrollment, is one of 5 that started in 2009, is one of 19 in phase 2, and was the 10th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

14 of the 37 studies testing Folfox protocol in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About Folfox protocol

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,181 Colorectal Neoplasms studies recruiting now, 764 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies testing Folfox protocol in Colorectal Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to determine the effect of adecatumumab alone or following FOLFOX in patients with R0 resected liver metastases from CRC (colorectal carcinoma) and to compare the effect to FOLFOX alone.

03

Conditions studied

  • Liver Metastases
  • Colorectal Cancer

Keywords

  • Colorectal carcinoma
  • Liver metastases (only)
  • R0 resection
  • R0 resection of liver metastases from colorectal cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histopathologically confirmed complete resection (R0) of liver from colorectal adenocarcinoma
  • Age ≥18 years
  • performance status ≤ 2
  • Patient was informed, has read and understood the patient information / form and has given written informed consent

Exclusion criteria

Exclusion Criteria:

  • Extra-hepatic distant or locally recurrent disease at time of enrolment
  • chemotherapy of liver metastases prior to surgery
  • Any anticancer chemotherapy within 4 weeks prior to study entry
  • Start of Oxaliplatin-based chemotherapy within 9 months prior to study entry
  • Any biological anticancer therapy or immunotherapy within 4 weeks prior to study entry
  • Any radiotherapy or radio frequency ablation (RFA) to the liver prior to surgery
  • Treatment with any product within a time range of 4-5 half-lives (t½) prior to study entry
  • Acute or chronic pancreatitis or history of alcohol induced pancreatitis
  • Liver cirrhosis, acute hepatitis or chronic hepatic disease
  • Any unresolved complications from prior surgery
  • Persistent neuropathy
  • History of other within 5 years prior to study start, with the exception of basal cell carcinoma of the skin, carcinoma in situ of the cervix and Ductal Carcinoma in Situ (DCIS)
  • History of inflammatory bowel disease
  • Active severe infection, any other concurrent disease or medical condition that is deemed to interfere with the conduct of the study as judged by the investigator
  • Use of immune-suppressive agents such as the regular use of systemic
  • positivity
  • Known or intolerability to immunoglobulins in general, other recombinant human or humanized antibodies, Folinic Acid, 5-Fluorouracil, Oxaliplatin or a component of the study drug formulations, known dihydropyrimidine dehydrogenase (DPD) deficiency
  • Pregnant or nursing women
  • Women of or male patients not willing to use an effective form of during treatment phase of the study and at least 6 months thereafter
  • Not willing or incapable to comply with all study visits and assessments
  • Placed into an institution due to juridical or regulatory ruling
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    1

    Adecatumumab alone

    Drug: Adecatumumab

  • Experimental
    2

    FOLFOX 4 followed by Adecatumumab

    Drug: Adecatumumab and FOLFOX

  • Active comparator
    3

    FOLFOX 4 alone

    Drug: FOLFOX 4

Interventions

  • Adecatumumab,6-9mg/kg, every 14 days, 24 cycles

    Also known as: MT201

  • DrugAdecatumumab and FOLFOX

    Drug pages: Adecatumumab · Folfox protocol

    FOLFOX 4, every 14 days, 12 cycles followed by Adecatumumab, 6-9mg/kg, every 14 days, 12 cycles

  • DrugFOLFOX 4

    FOLFOX 4, every 14 days, 12 cycles

06

What researchers measure

Primary outcomes

  1. Disease free survival rate (DFS)

    Time frame: 1 year

Secondary outcomes

  1. time to relapse

    Time frame: 1 year

  2. Incidence of AEs

    Time frame: 1 year

  3. Quality of Life

    Time frame: 1 year

07

Study locations

16 sites
  • Centre Paul Strauss
    Strasbourg, 67065, France
  • Zentralklinikum Augsburg
    Augsburg, 86156, Germany
  • Klinikum am Bruderwald, Sozialstiftung Bamberg
    Bamberg, 96049, Germany
  • Charité Campus Virchow Klinikum
    Berlin, 13353, Germany
  • Klinikum der Heinrich-Heine Universität
    Düsseldorf, 40489, Germany
  • J.W. Goethe-Universität
    Frankfurt, 60590, Germany
  • Martin-Luther Universität
    Halle, 06120, Germany
  • Medizinische Hochschule Hannover
    Hannover, 30625, Germany
  • Universitätsklinikum Leipzig
    Leipzig, 04103, Germany
  • Klinikum Magdeburg gGmbH
    Magdeburg, 39130, Germany
  • Klinikum der Johannes-Gutenberg Universität
    Mainz, 55131, Germany
  • Klinikum Mannheim GmbH Universitätsklinikum
    Mannheim, 68167, Germany
  • Universitätsklinikum der LMU Grosshadern
    München, 81377, Germany
  • Städtisches Klinikum Neuperlach
    München, 81737, Germany
  • Klinikum Oldenburg gGmbH
    Oldenburg, 26133, Germany
  • Klinikum der Universität Regensburg
    Regensburg, 93053, Germany
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2009, a primary completion of Jul 2011 and a completion of Nov 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2009
First posted
Mar 23, 2009
Start
Mar 2009
Primary completionActual
Jul 2011
CompletionActual
Nov 2011
Last update
Nov 11, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 11, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00866944
Responsible party
Sponsor
First posted
Mar 23, 2009
Start date
Mar 2009
Primary completion
Jul 2011
Completion
Nov 2011
Last update
Nov 11, 2011

Study contacts

Peter Neuhaus, Prof. Dr.
principal investigator · Charité Campus Virchow Klinikum, Berlin
Patrick Dufour, Pr. Dr.
principal investigator · Centre Paul Strauss, Strasbourg

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Adecatumumab · Folfox protocol

Start the discussion